Renaissance Technologies’s XTL Biopharmaceuticals XTLB Stock Holding History

Renaissance Technologies’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,820	Closed	-$64K	–	4535
2021 Q4	$64K	Buy	5,820 +250	+4%	+$3.46K	﹤0.01%	3754
2021 Q3	$98K	Sell	5,570 -3,727	-40%	-$60K	﹤0.01%	3319
2021 Q2	$148K	Sell	9,297 -403	-4%	-$5.54K	﹤0.01%	3308
2021 Q1	$129K	Buy	9,700 +4,817	+99%	+$66.4K	﹤0.01%	3204
2020 Q4	$59K	Buy	+4,883	New	+$46.3K	﹤0.01%	3311

Other funds holding XTLB

Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return

Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies's XTLB Position: Q1 2022 in Review

Renaissance Technologies sold out of XTL Biopharmaceuticals (XTLB) in Q1 2022, closing a stake of 5,820 shares — an estimated $64K sold.

Renaissance Technologies first reported a position in XTLB in Q4 2020 and held it in 5 quarters. The position peaked at $148K in Q2 2021. 4 funds tracked by Wall St. Rank hold XTLB as of Q1 2022.

Renaissance Technologies reported no remaining XTL Biopharmaceuticals position as of Q1 2022 after selling out during the quarter.
Renaissance Technologies sold 5,820 XTL Biopharmaceuticals shares in Q1 2022, an estimated $64K.
Renaissance Technologies first reported a position in XTL Biopharmaceuticals in Q4 2020 and held it in 5 quarters.
Renaissance Technologies's XTL Biopharmaceuticals position peaked at $148K in Q2 2021.
4 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2022.

Based on Renaissance Technologies's 13F filing for Q1 2022, filed 13 May 2022.